AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION DIN 02495929
Status: Marketed
Holder: SANDOZ CANADA INCORPORATED
Molecule: AMOXICILLIN (AMOXICILLIN SODIUM)
Available to quote
Health Canada record
| Active ingredient(s) | AMOXICILLIN (AMOXICILLIN SODIUM) 1000 MG; CLAVULANIC ACID (CLAVULANATE POTASSIUM) 200 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR |
| Original market date | 03-Jul-2020 |
| Current status date | 03-Jul-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AMOXICILLIN (AMOXICILLIN SODIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02495910 | AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | SANDOZ CANADA INCORPORATED | Powder For Solution | AMOXICILLIN (AMOXICILLIN SODIUM) 500 MG; CLAVULANIC ACID (CLAVULANATE POTASSIUM) 100 MG | Marketed |
| 02495937 | AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | SANDOZ CANADA INCORPORATED | Powder For Solution | AMOXICILLIN (AMOXICILLIN SODIUM) 2000 MG; CLAVULANIC ACID (CLAVULANATE POTASSIUM) 200 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23151 | 2020-01-28 | New Drug Submission (NDS) |